Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability

STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability

Thumbnail Image
Download
Name

Luo-2012-STK33 kinase inhibit.pdf

Size

1.54 MB

Format

Adobe PDF

Checksum (MD5)

af2f11b7bc7061a2bcdfc20d213f48f3

Author(s)
Luo, Tuoping
•
Masson, Kristina
•
Jaffe, Jacob D.
•
Silkworth, Whitney
•
Lee, Nathan Ross
•
Scherer, Christina A.
•
Scholl, Claudia
•
Frohling, Stefan
•
Stern, Andrew M.
•
Schreiber, Stuart L.
more
Date Issued
February 2012
Journal
Proceedings of the National Academy of Sciences
Publisher
National Academy of Sciences
Citation
Luo, T. et al. “STK33 Kinase Inhibitor BRD-8899 Has No Effect on KRAS-dependent Cancer Cell Viability.” Proceedings of the National Academy of Sciences 109.8 (2012): 2860–2865. Copyright ©2012 by the National Academy of Sciences
Version
Final published version
Abstract
Approximately 30% of human cancers harbor oncogenic gain-of-function mutations in KRAS. Despite interest in KRAS as a therapeutic target, direct blockade of KRAS function with small molecules has yet to be demonstrated. Based on experiments that lower mRNA levels of protein kinases, KRAS-dependent cancer cells were proposed to have a unique requirement for the serine/threonine kinase STK33. Thus, it was suggested that small-molecule inhibitors of STK33 might have therapeutic benefit in these cancers. Here, we describe the development of selective, low nanomolar inhibitors of STK33’s kinase activity. The most potent and selective of these, BRD8899, failed to kill KRAS-dependent cells. While several explanations for this result exist, our data are most consistent with the view that inhibition of STK33’s kinase activity does not represent a promising anti-KRAS therapeutic strategy.
MIT Department
Massachusetts Institute of Technology. Engineering Systems Division
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
http://hdl.handle.net/1721.1/72564
DOI of Published Version
https://doi.org/10.1073/pnas.1120589109
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.